Dr. Michael I. Jacobs to Chair Advisory Board
August 6, 2018 (Richmond, California)… AIM at Melanoma, the trusted global leader in melanoma education, advocacy, and research, announced that Dr. Michael I. Jacobs will chair AIM’s Advisory Board.
Dr. Michael I. Jacobs is a Manhattan-based, Board Certified dermatologist with extensive experience in office practice, research, and education. He is renowned for his extraordinary knowledge, for his practiced eye, and particularly for his early detection of skin cancer and melanoma. In addition to his position as Associate Attending Dermatologist at New York Presbyterian Hospital (NYPH) and The Hospital for Special Surgery (HSS), Dr. Jacobs is Clinical Associate Professor of Dermatology at Weill Cornell Medical College, where he teaches Cornell medical students and Cornell dermatology residents. He is a fellow of the American Academy of Dermatology and the American Society for Dermatologic Surgery as well as a member of the American College of Rheumatology. Dr. Jacobs is also the official team dermatologist of the New York Mets.
“I am thrilled that Dr. Jacobs has accepted the role of Chair of our Advisory Board,” noted Val Guild, President and Co-Founder of AIM at Melanoma. “His expertise detecting early melanomas sets him apart in the world of dermatology. His passion for melanoma education, early detection, and research is second to none. Together, AIM, Michael Jacobs, and our Advisory Board will do great things for melanoma.”
AIM’s Advisory Board will work with the Foundation to achieve its goals in education, advocacy, and research. The Board will be based in New York City, but, like AIM, make a global impact.
“I admire AIM’s work, and I am excited about what we can do for melanoma education and research,” said Dr. Jacobs. “In a time of soaring melanoma rates, it is critical that we commit ourselves to combat this disease—and preventing it as much as possible in the first place.”
ABOUT AIM AT MELANOMA FOUNDATION: Melanoma is one of the fastest growing cancers in the United States and worldwide. It’s one of the most complex forms of cancer and has the most mutations of all solid cancers. Founded in 2004, AIM at Melanoma is the largest international melanoma foundation focused on the discovery of the cure for melanoma. AIM’s global research initiatives include The International Melanoma Tissue Bank Consortium, The Melanoma International Collaboration for Adaptive Trials, and the International Melanoma Working Group. AIM at Melanoma also provides education, connection to resources, and opportunities for meaningful engagement to help patients and caregivers/families better face the challenges of melanoma.